Italy· 035606110
ARIXTRA*10 siringhe SC 5 mg 0,4 ml
A fondaparinux product containing fondaparinux, registered in Italy by VIATRIS HEALTHCARE LIMITED, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Fondaparinux is registered in 17 of 19 countries.
Countries holding a registration under ATC B01AX05 (fondaparinux), each read from that country’s own register.
- This record: Italy
- 11 of them publish a price we can compare per daily dose
Fondaparinux · ATC B01AX05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Active substance
- Fondaparinux
- Manufacturer
- VIATRIS HEALTHCARE LIMITED
- Country
- Italy (IT)
- ATC code
- B01AX05
- ATC class
- Fondaparinux
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic035606110ARIXTRA*10 siringhe SC 5 mg 0,4 mlEUR 138.04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for fondaparinux.
Graded by severity as the source publishes them — 106 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fondaparinux · interactions on record
158 records
- 106 severe
- 52 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fondaparinux in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaARIXTRAVIATRIS HEALTHCARE LIMITED, Dublin
- United StatesArixtraMylan Institutional LLC
- United KingdomArixtra 1.5mg/0.3ml solution for injection pre-filled syringesViatris UK Healthcare Ltd
- IrelandArixtraViatris Healthcare Limited
- FinlandArixtraViatris Healthcare Limited
- SwitzerlandArixtra
- SpainARIXTRA 1,5 MG/0,3 ML SOLUCION INYECTABLE, JERINGA PRECARGADAViatris Healthcare Limited
- IcelandArixtraViatris Healthcare Limited
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Germany · Fondaparinux-Natrium Beta
- France · Fondaparinux Sodique Aspen
- United Kingdom (Northern Ireland) · Fondaparinux Sodium Dr. Reddy's
- Ireland · Fondaparinux Sodium Aspen
- Iceland · Arixtra
- Liechtenstein · Arixtra
- Norway · Arixtra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0776b4b-ece1-49fb-9ec2-c4b34f5b9a81 GET /v1/drugs/c0776b4b-ece1-49fb-9ec2-c4b34f5b9a81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 138.04,
"source": "aifa",
"currency": "EUR",
"strength": "FONDAPARINUX 5MG 0,4ML 10 UNITA' USO PARENTERALE",
"substance": "Fondaparinux",
"equivalence_group": "MCD",
"transparency_flag": null
}See everything about fondaparinux.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.